1702 related articles for article (PubMed ID: 24101439)
1. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
2. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.
Kooijmans EC; Bökenkamp A; Tjahjadi NS; Tettero JM; van Dulmen-den Broeder E; van der Pal HJ; Veening MA
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008944. PubMed ID: 30855726
[TBL] [Abstract][Full Text] [Related]
3. Hepatic late adverse effects after antineoplastic treatment for childhood cancer.
Mulder RL; Bresters D; Van den Hof M; Koot BG; Castellino SM; Loke YKK; Post PN; Postma A; Szőnyi LP; Levitt GA; Bardi E; Skinner R; van Dalen EC
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD008205. PubMed ID: 30985922
[TBL] [Abstract][Full Text] [Related]
4. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
5. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
8. Long-term nephrotoxicity in adult survivors of childhood cancer.
Dekkers IA; Blijdorp K; Cransberg K; Pluijm SM; Pieters R; Neggers SJ; van den Heuvel-Eibrink MM
Clin J Am Soc Nephrol; 2013 Jun; 8(6):922-9. PubMed ID: 23411430
[TBL] [Abstract][Full Text] [Related]
9. Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy.
Interiano RB; Delos Santos N; Huang S; Srivastava DK; Robison LL; Hudson MM; Green DM; Davidoff AM
Cancer; 2015 Jul; 121(14):2449-56. PubMed ID: 25832759
[TBL] [Abstract][Full Text] [Related]
10. Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience.
Schiavetti A; Pedetti V; Varrasso G; Marrucci O; Celani C; Andreoli G; Bonci E
Pediatr Hematol Oncol; 2018 Apr; 35(3):167-176. PubMed ID: 30230941
[TBL] [Abstract][Full Text] [Related]
11. Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literature.
O'Sullivan D
Ir J Med Sci; 2017 Feb; 186(1):49-55. PubMed ID: 27339643
[TBL] [Abstract][Full Text] [Related]
12. Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study.
Mulder RL; Knijnenburg SL; Geskus RB; van Dalen EC; van der Pal HJ; Koning CC; Bouts AH; Caron HN; Kremer LC
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1736-46. PubMed ID: 24064520
[TBL] [Abstract][Full Text] [Related]
13. The Dutch Childhood Cancer Survivor Study (DCCSS)-LATER 2 kidney analysis examined long-term glomerular dysfunction in childhood cancer survivors.
Kooijmans ECM; van der Pal HJH; Pluijm SMF; van der Heiden-van der Loo M; Kremer LCM; Bresters D; van Dulmen-den Broeder E; van den Heuvel-Eibrink MM; Loonen JJ; Louwerens M; Neggers SJC; Ronckers C; Tissing WJE; de Vries ACH; Kaspers GJL; Veening MA; Bökenkamp A;
Kidney Int; 2022 Nov; 102(5):1136-1146. PubMed ID: 35772499
[TBL] [Abstract][Full Text] [Related]
14. [Renal late effects in patients treated for cancer in childhood].
Sudour-Bonnange H; Vanrenterghem A; Nobili F; Guigonis V; Boudailliez B
Bull Cancer; 2015; 102(7-8):627-35. PubMed ID: 25935232
[TBL] [Abstract][Full Text] [Related]
15. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
16. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
17. Long-term renal function in unilateral non-syndromic renal tumor survivors treated according to International Society of Pediatric Oncology protocols.
Schiavetti A; Altavista P; De Luca L; Andreoli G; Megaro G; Versacci P
Pediatr Blood Cancer; 2015 Sep; 62(9):1637-44. PubMed ID: 25893525
[TBL] [Abstract][Full Text] [Related]
18. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
[TBL] [Abstract][Full Text] [Related]
19. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
